# US 2019/0293661 A1 · Method of predicting responsiveness of wet amd patient to anti-vegf therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0293661 A1
- Document ID: US20190293661A1
- Status: Published application
- Kind: A1
- Application number: 16/465,703
- Filed: 2017-11-30
- Published: 2019-09-26
- Earliest claimed: 2016-12-01
- Assignees: Santen Pharmaceutical Co., Ltd.
- Applicants: Santen Pharmaceutical Co., Ltd.
- Inventors: Keiichi Shibagaki; Masanao Toshimori; Koji Oka; Shingo Maeda; Hiroshi Inoue
- Web page: https://patentgrep.com/patent/US20190293661A1

## CPC

- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/495: Transforming growth factor [TGF]
- G01N 2333/51: Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- G01N 2333/515: Angiogenesic factors; Angiogenin
- G01N 2800/16: Ophthalmology
- G01N 2800/164: Retinal disorders, e.g. retinopathy
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The disclosure provides a method of predicting the responsiveness of a wet AMD patient to anti-VEGF therapy comprising (1) determining the level of at least one marker protein selected from the group consisting of TGF-beta, BMP9, angiopoietin-1, and angiopoietin-2 in a blood, plasma or serum sample obtained from the patient, and (2) predicting the responsiveness of the patient to the anti-VEGF therapy with reference to the level determined in step (1), as well as a diagnostic agent for use in the method.

## Claims

### Claim 1

A method of predicting the responsiveness of a wet AMD patient to anti-VEGF therapy, comprising:
(1) determining the level of at least one marker protein selected from the group consisting of TGF-beta, BMP9, angiopoietin-1, and angiopoietin-2 in a blood, plasma or serum sample obtained from the patient, and
(2) predicting the responsiveness of the patient to the anti-VEGF therapy with reference to the level determined in step (1).

### Claim 2 (depends on 1)

The method according to claim 1, wherein the responsiveness is predicted by comparing the determined level to a cutoff value predetermined for the marker protein in step (2).

### Claim 3 (depends on 2)

The method according to claim 2, wherein the patient is predicted to be responsive to the anti-VEGF therapy when the determined level of TGF-beta is higher than a cutoff value for TGF-beta.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the patient is predicted to be responsive to the anti-VEGF therapy when the determined level of BMP9 is lower than a cutoff value for BMP9.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the patient is predicted to be responsive to the anti-VEGF therapy when the determined level of TGF-beta is higher than a cutoff value for TGF-beta and the determined level of BMP9 is lower than a cutoff value for BMP9.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the patient is predicted to be responsive to the anti-VEGF therapy when the determined level of angiopoietin-1 is higher than a cutoff value for angiopoietin-1.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the patient is predicted to be responsive to the anti-VEGF therapy when the determined level of angiopoietin-2 is lower than a cutoff value for angiopoietin-2.

### Claim 8 (depends on 2)

The method according to claim 2, wherein the patient is predicted to be responsive to the anti-VEGF therapy when the determined level of angiopoietin-1 is higher than a cutoff value for angiopoietin-1 and the determined level of angiopoietin-2 is lower than a cutoff value for angiopoietin-2.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the patient has not received the anti-VEGF therapy for treating wet AMD.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the patient is receiving or has received anti-VEGF therapy for treating wet AMD.

### Claim 11

A diagnostic agent for predicting the responsiveness of a wet AMD patient to anti-VEGF therapy, comprising at least one antibody selected from the group consisting of anti-TGF-beta antibody, anti-BMP9 antibody, anti-angiopoietin-1 antibody, and anti-angiopoietin-2 antibody.
